Atypical lipomatous tumor (lowgrade softtissue cancer) well differentiated liposarcoma
Conditions
Interventions
None listed
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: - Aged >=18 years - Primary or recurrent lipomatous tumor suspected for lipoma or well-differentiated liposarcoma - Adequate understanding of the Dutch or English language (to fill out the HRQoL questionnaires)
Exclusion criteria
Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: - Tumor localization in the mediastinum, retroperitoneum or testis/scrotum - Diagnosis through excisional biopsy - Any type of treatment for the current tumor (i.e. in case of recurrence, treatment of the prior tumor(s) is allowed) - Signs/suspicion of dedifferentiation in the biopsy specimen at time of diagnosis - Unable to undergo regular MRI-scans (for example because of a pacemaker, claustrophobia) - Systemic treatment for any other concurrent malignancy - Currently receiving radiotherapy at affected site for other concurrent disease - Incapable to understand the study, to sign informed consent or to fill out the HRQoL-questionnaires
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study endpoints are choice of treatment (i.e. AS or surgery) to determine the feasibility of AS and the occurence of dedifferentiation to determine safety. AS will be considered feasible if at least 25% of the patients prefers AS over surgery, of whom at least 50% is still being treated with AS after one year of follow-up. AS will be considered safe if dedifferentiation occurs in | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes are evaluating tumor growth/progression, motives for treatment decision making and switching, validation of the radiomics model, to assess Health-related Quality of life and to develop a Biobank for future translational research. | — |
Countries
Netherlands
Outcome results
None listed